

Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer

Coding Specifications

Codes required to document patient has breast cancer and a visit occurred:

An ICD-9-CM diagnosis code for breast cancer and a CPT code are required to identify patients to be included in this measure.

All measure specific coding should be reported on the claim(s) representing the eligible encounter.

Breast cancer ICD-9-CM diagnosis codes

- 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 (malignant neoplasm of female breast)
- V10.3 (history of Breast Cancer)

AND

CPT codes

- 99201, 99202, 99203, 99204, 99205
- 99212, 99213, 99214, 99215

Quality codes for this measure:

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate code or combination of codes.)

- **CPT II 3315F:** Estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer
- **CPT II 3316F:** Estrogen receptor (ER) and progesterone receptor (PR) negative breast cancer
- **CPT II 3316F-8P:** No documentation of estrogen receptor (ER) and progesterone receptor (PR) status

- **CPT II 3374F:** AJCC Breast Cancer Stage I: T1C (tumor size > 1cm to 2cm), documented
- **CPT II 3376F:** AJCC Breast Cancer Stage II, documented
- **CPT II 3378F:** AJCC Breast Cancer Stage III, documented
- **CPT II 3370F:** AJCC Breast Cancer Stage 0, documented
- **CPT II 3372F:** AJCC Breast Cancer Stage I: T1 mic, T1a or T1b (tumor size < 1cm), documented
- **CPT II 3380F:** AJCC Breast Cancer Stage IV, documented
- **CPT II 3370F-8P:** No documentation of cancer stage
- **CPT II 4179F:** Tamoxifen or aromatase inhibitor (AI) prescribed
- **CPT II 4179F-1P:** Documentation of medical reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient's disease has progressed to metastatic, patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient's diagnosis date was ≥ 5 years from reporting date, not indicated, contraindicated, other medical reason)
- **CPT II 4179F-2P:** Documentation of patient reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient refusal, patient declined, social, economic, religious, other patient reason)
- **CPT II 4179F-3P:** Documentation of system reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient is currently enrolled in a clinical trial, other reasons attributable to health care delivery system)
- **CPT II 4179F-8P:** Tamoxifen or aromatase inhibitor **not** prescribed, reason not otherwise specified

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

CPT® contained in the Measures specifications is copyright 2010 American Medical Association.

Physician Quality Reporting System 2011 Measure 71, Effective Date 01/01/2011

© 2007 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.
CPT® Copyright 2010 American Medical Association.